Tanya Lewis - Jun 13, 2023 Form 4 Insider Report for Replimune Group, Inc. (REPL)

Signature
/s/ Shawn Glidden, attorney-in-fact
Stock symbol
REPL
Transactions as of
Jun 13, 2023
Transactions value $
-$309,395
Form type
4
Date filed
6/15/2023, 09:01 PM
Previous filing
Jun 2, 2023
Next filing
Jun 3, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction REPL Common Stock Sale -$290K -12K -8.13% $24.10 136K Jun 13, 2023 Direct F1, F2
transaction REPL Common Stock Sale -$19.2K -817 -0.6% $23.45 135K Jun 13, 2023 Direct F1, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on March 15, 2023, that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended.
F2 The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.59 to $24.57. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F3 The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.34 to $23.55. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F4 Following the sales reported on this form 4, the reporting person continues to beneficially own 135,293 shares of the Issuer's common stock. The reporting person also holds options to acquire an aggregate of 248,750 shares of the Issuer's common stock, 80,259 of which are exercisable as of the date hereof.